Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 111

1.

Analysis of hepatitis B virus genotyping and drug resistance gene mutations based on massively parallel sequencing.

Han Y, Zhang Y, Mei Y, Wang Y, Liu T, Guan Y, Tan D, Liang Y, Yang L, Yi X.

J Virol Methods. 2013 Nov;193(2):341-7. doi: 10.1016/j.jviromet.2013.06.015. Epub 2013 Jun 14.

PMID:
23773806
2.

Profile of HBV antiviral resistance mutations with distinct evolutionary pathways against nucleoside/nucleotide analogue treatment among Chinese chronic hepatitis B patients.

Yang JX, Liu BM, Li XG, Yan CH, Xu J, Sun XW, Wang YH, Jiao XJ, Yan L, Dong JP, Hou CS, Abuduheilili X, Li T, Zhuang H.

Antivir Ther. 2010;15(8):1171-8. doi: 10.3851/IMP1677.

PMID:
21149924
5.

[Mutation patterns in the RT region of hepatitis B virus P gene in patients treated with nucleoside/nucleotide analogs].

DENG J, ZHANG DH, YU DM, CHEN L, ZHANG XX.

Zhonghua Gan Zang Bing Za Zhi. 2009 May;17(5):342-5. Chinese.

PMID:
19497198
6.

Characterization of hepatitis virus B isolated from a multi-drug refractory patient.

Wei C, Chong YT, Wen JZ, Li YW, Li G.

Virus Res. 2011 Jan;155(1):254-8. doi: 10.1016/j.virusres.2010.10.018. Epub 2010 Oct 21.

PMID:
20970466
7.

Low-level persistence of drug resistance mutations in hepatitis B virus-infected subjects with a past history of Lamivudine treatment.

Margeridon-Thermet S, Svarovskaia ES, Babrzadeh F, Martin R, Liu TF, Pacold M, Reuman EC, Holmes SP, Borroto-Esoda K, Shafer RW.

Antimicrob Agents Chemother. 2013 Jan;57(1):343-9. doi: 10.1128/AAC.01601-12. Epub 2012 Oct 31.

8.

Snapshot on drug-resistance rate and profiles in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice.

Salpini R, Alteri C, Cento V, Pollicita M, Micheli V, Gubertini G, De Sanctis GM, Visca M, Romano S, Sarrecchia C, Andreoni M, Angelico M, Parruti G, Svicher V, Perno CF.

J Med Virol. 2013 Jun;85(6):996-1004. doi: 10.1002/jmv.23567.

PMID:
23588725
9.
10.

Chronic hepatitis B: preventing, detecting, and managing viral resistance.

Keeffe EB, Dieterich DT, Pawlotsky JM, Benhamou Y.

Clin Gastroenterol Hepatol. 2008 Mar;6(3):268-74. doi: 10.1016/j.cgh.2007.12.043. Review.

PMID:
18328434
11.

Evolution of primary and compensatory lamivudine resistance mutations in chronic hepatitis B virus-infected patients during long-term lamivudine treatment, assessed by a line probe assay.

Libbrecht E, Doutreloigne J, Van De Velde H, Yuen MF, Lai CL, Shapiro F, Sablon E.

J Clin Microbiol. 2007 Dec;45(12):3935-41. Epub 2007 Oct 3.

12.

Genotypic resistance profile of hepatitis B virus (HBV) in a large cohort of nucleos(t)ide analogue-experienced Chinese patients with chronic HBV infection.

Liu Y, Wang C, Zhong Y, Li X, Dai J, Ren X, Xu Z, Li L, Yao Z, Ji D, Wang L, Zhang L, Wong VW, Zoulim F, Xu D.

J Viral Hepat. 2011 Apr;18(4):e29-39. doi: 10.1111/j.1365-2893.2010.01360.x. Epub 2010 Sep 6.

PMID:
21392168
13.

Analysis of potential antiviral resistance mutation profiles within the HBV reverse transcriptase in untreated chronic hepatitis B patients using an ultra-deep pyrosequencing method.

Ciftci S, Keskin F, Cakiris A, Akyuz F, Pinarbasi B, Abaci N, Dincer E, Badur S, Kaymakoglu S, Ustek D.

Diagn Microbiol Infect Dis. 2014 May;79(1):25-30. doi: 10.1016/j.diagmicrobio.2014.01.005. Epub 2014 Jan 14.

PMID:
24630522
14.

Performance of LigAmp assay for sensitive detection of drug-resistant hepatitis B virus minor variants in comparison with standard nucleotide sequencing.

Ismail AM, Sachithanandham J, Eapen CE, Kannangai R, Abraham P.

Mol Diagn Ther. 2014 Dec;18(6):655-63. doi: 10.1007/s40291-014-0119-y.

PMID:
25208639
15.

Long-term monitoring drug resistance by ultra-deep pyrosequencing in a chronic hepatitis B virus (HBV)-infected patient exposed to several unsuccessful therapy schemes.

Sede M, Ojeda D, Cassino L, Westergaard G, Vazquez M, Benetti S, Fay F, Tanno H, Quarleri J.

Antiviral Res. 2012 May;94(2):184-7. doi: 10.1016/j.antiviral.2012.03.003. Epub 2012 Mar 20.

PMID:
22453135
16.

Analysis of hepatitis B virus drug-resistant mutant haplotypes by ultra-deep pyrosequencing.

Ko SY, Oh HB, Park CW, Lee HC, Lee JE.

Clin Microbiol Infect. 2012 Oct;18(10):E404-11. doi: 10.1111/j.1469-0691.2012.03951.x. Epub 2012 Jul 3.

17.

Clinical evaluation of oligonucleotide microarrays for the detection of HBV mutants associated with lamivudine resistance.

Chen LY, Huang J, Zhang XP, Qiao P, Zhang W, Yang NM, Liu HJ, Geng YY, Qiu JM, Wang SQ.

Pharmacogenomics. 2005 Oct;6(7):721-30.

PMID:
16207149
18.

Monitoring drug resistance in chronic hepatitis B virus (HBV)-infected patients during lamivudine therapy: evaluation of performance of INNO-LiPA HBV DR assay.

Lok AS, Zoulim F, Locarnini S, Mangia A, Niro G, Decraemer H, Maertens G, Hulstaert F, De Vreese K, Sablon E.

J Clin Microbiol. 2002 Oct;40(10):3729-34.

19.

Genotype-specific mutations in the polymerase gene of hepatitis B virus potentially associated with resistance to oral antiviral therapy.

Mirandola S, Sebastiani G, Rossi C, Velo E, Erne EM, Vario A, Tempesta D, Romualdi C, Campagnolo D, Alberti A.

Antiviral Res. 2012 Dec;96(3):422-9. doi: 10.1016/j.antiviral.2012.09.014. Epub 2012 Sep 28.

PMID:
23026293
20.

Monitoring of therapy in patients with chronic hepatitis B virus.

Arrese E, Basaras M, Blanco S, Ruiz P, Cisterna R.

Eur J Gastroenterol Hepatol. 2010 Jun;22(6):736-40. doi: 10.1097/MEG.0b013e32832e0a44.

PMID:
19550344

Supplemental Content

Support Center